Multiple Sclerosis Therapeutics Market: Global Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2017-2021 and Forecast 2022-2028

$ PRICE - $ 3,000.00$ 8,900.00

Multiple Sclerosis Therapeutics Market: By Product Type (Immunosuppressants and Immunomodulators), Route Of Administration Type (Oral, Injectable, and Intravenous) and Geography

 

$ PRICE - $ 3,000.00$ 8,900.00
Clear selection
Clear
$ PRICE - $ 3,000.00$ 8,900.00
FacebookTwitterLinkedinEmail
SKU: N/A Category:

Report

Description

Multiple Sclerosis Therapeutics Market size is expected to be valued at USD 27,534.2 million in 2022 and is expected to grow at a CAGR of 5.6% in 2022-2028. Multiple sclerosis is a chronic immune-mediated inflammatory disease that disturbs nerve cells in the brain and spinal cord, producing demyelination, neurodegeneration, and axonal transection. muscle relaxants, physical therapy, antidepressants, and injectable, infused, and oral medications are some of the most extensively used therapies. Glatiramer acetate and Interferon-beta are injectable treatments that are provided into the muscle or under the skin, oral medications are teriflunomide, cladribine, and dimethyl fumarate; and intravenous infusion therapies are ocrelizumab, natalizumab, and alemtuzumab. The growing prevalence of multiple sclerosis can lead to the growth of the multiple sclerosis therapeutics markets. Moreover, growing healthcare expenditure which facilitates in refining its infrastructure, and increasing initiatives by private and public organizations to spread awareness are some primary factors that can boost the global multiple sclerosis therapeutics markets. Apart from these, increasing initiatives by private and public organizations to increase awareness, an increase in disposable income, and a surge in the development of advanced interferon, monoclonal antibodies, immunomodulators, and immunosuppressants can also accelerate the market in the future. The growing geriatric population and incessantly changing lifestyles can also drive the global market further. However, some factors such as the high treatment cost of multiple sclerosis and the lack of skilled professionals, and the absence of good healthcare infrastructure in developing nations can restrain the growth of the market. The growing number of research and development events can create an opportunity for the growth of the global multiple sclerosis therapeutics markets.

 

Recent Market Developments:

In march 2021, Janssen Pharmaceutical, Inc. announced the U.S. FDA approval of Ponvory, an oral selective sphingosine-1-phosphate receptor 1 (S1P1) modulator to cure adults with relapsing forms of multiple sclerosis.

In August 2020, Novartis AG announced the U.S. Food and Drug Administration (FDA) approval of Kesimpta (ofatumumab, formerly OMB157) as a subcutaneous injection used for the treatment of relapsing forms of multiple sclerosis

Multiple Sclerosis Therapeutics Market

MARKET SUMMARY
-
5.6%
  • Study Period– 2022 – 2028
  • Base Year– 2021
  • CAGR– 5.6%
  • Largest Market– Asia Pacific
  • Fastest Growing Market–  North America

Multiple Sclerosis Therapeutics Market

  • The multiple sclerosis therapeutics market report gives comprehensive outlook across the region with special emphasis on key regions such as North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  • The multiple sclerosis therapeutics market is segmented based on based on product type, route of administration, and region.
Key Players
  • Biogen (U.S.)
  • Pfizer Inc. (U.S.)
  • Hoffmann-La Roche Ltd. (Switzerland)
  • Novartis AG (Switzerland)
  • Merck & Co., Inc. (U.S.)
Multiple Sclerosis Therapeutics Market Dynamics

One of the major reasons for the growth of the global multiple sclerosis therapeutics markets is the substantial research and development investment by key players. Numerous novel molecules are being examined for the cure of multiple sclerosis. Some of the important pharmaceutical companies highlight the development of the disabilities related to multiple sclerosis. The pipeline portfolio of numerous companies comprises agents with diverse mechanisms of action, which is expected to enhance their demand from doctors, directing to alteration of the treatment algorithm in the few years.


North-America Got Significant Share

Multiple Sclerosis Therapeutics Market

North America is dominating the global multiple sclerosis therapeutics markets, due to the growing research and development investment, new launches of the products, and increasing demand for molecular antibody drugs and immunosuppressants. Moreover, government initiatives to spread awareness concerning the treatment and diagnosis of multiple sclerosis and lucrative health insurance and reimbursement policies by the government have also attributed to the growth of the market.

Latin America
Latin-America
North-America
North-America
Europe
Europe
Asia Pacific
Asia-Pacific
Middle East
Middle East

Key

Features of the Report

  • The multiple sclerosis therapeutics market report provides granular level information about the market size, regional market share, historic market (2017-2021), and forecast (2022-2028)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments, and start-up details that are actively working in the market
  • The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
Multiple Sclerosis Therapeutics Market Segmentation


Location

GEOGRAPHY

Frequently Asked Questions

The primary factors that drive the market are the growing focus on research and development to innovate novel drugs by chief market players, new launches of products, growing government initiatives to expand the availability of care and treatment, and the increasing prevalence of multiple sclerosis.

Biogen (U.S.), Pfizer Inc. (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Novartis AG (Switzerland), Merck & Co., Inc. (U.S.), Sanofi (France), Teva Pharmaceutical Industries Ltd. (Israel), Janssen Pharmaceuticals, Inc. (Johnson & Johnson Corporation) (New Jersey), and Bristol-Myers Squibb Company (U.S.) are the key players of the market.

North America is dominating the multiple sclerosis therapeutics markets.

Oral placed under the route of administration type segment is the fastest-growing segment of the market.


Report

Table Of Content

1. Executive Summary
2. Global Multiple Sclerosis Therapeutics Market Introduction
2.1. Global Multiple Sclerosis Therapeutics Market – Taxonomy
2.2. Global Multiple Sclerosis Therapeutics Market –Definitions
2.2.1. Product Type
2.2.2. Route Of Administration
2.2.3. By Region
3. Global Multiple Sclerosis Therapeutics Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global Multiple Sclerosis Therapeutics Market Dynamic Factors – Impact Analysis
3.6. Global Multiple Sclerosis Therapeutics Market – Competition Landscape
3.7. Epidemiology
4. Global Multiple Sclerosis Therapeutics Market Analysis, 2017-2021 and Forecast, 2022-2028
4.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Opportunity Analysis
5. Global Multiple Sclerosis Therapeutics Market, By Product Type, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
5.1. Immunosuppressants
5.1.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.3. Market Opportunity Analysis
5.2. Immunomodulators
5.2.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.3. Market Opportunity Analysis
6. Global Multiple Sclerosis Therapeutics Market, By Route Of Administration, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
6.1. Oral
6.1.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.1.3. Market Opportunity Analysis
6.2. Injectable
6.2.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.2.3. Market Opportunity Analysis
6.3. Intravenous
6.3.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.3.3. Market Opportunity Analysis
7. Global Multiple Sclerosis Therapeutics Market Forecast, By Region, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
7.1. North America
7.1.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.1.3. Market Opportunity Analysis
7.2. Europe
7.2.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.2.3. Market Opportunity Analysis
7.3. Asia-Pacific
7.3.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.3.3. Market Opportunity Analysis
7.4. Latin America
7.4.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
7.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.4.3. Market Opportunity Analysis
7.5. Middle East and Africa
7.5.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
7.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.5.3. Market Opportunity Analysis
7.6. Global Multiple Sclerosis Therapeutics Market – Opportunity Analysis Index, By Product Type, By Route Of Administration, and Region, 2022-2028
8. North America Multiple Sclerosis Therapeutics Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
8.1. Product Type Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
8.1.1. Immunosuppressants
8.1.2. Immunomodulators
8.2. Route Of Administration Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
8.2.1. Oral
8.2.2. Injectable
8.2.3. Intravenous
8.3. Country Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
8.3.1. USA
8.3.2. Canada
8.4. North America Multiple Sclerosis Therapeutics Market – Opportunity Analysis Index, By Product Type, By Route Of Administration, and Country, 2022-2028
8.5. North America Multiple Sclerosis Therapeutics Market Dynamics – Trends
9. Europe Multiple Sclerosis Therapeutics Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
9.1. Product Type Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
9.1.1. Immunosuppressants
9.1.2. Immunomodulators
9.2. Route Of Administration Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
9.2.1. Oral
9.2.2. Injectable
9.2.3. Intravenous
9.3. Country Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
9.3.1. Germany
9.3.2. UK
9.3.3. France
9.3.4. Spain
9.3.5. Italy
9.3.6. Rest of Europe
9.4. Europe Multiple Sclerosis Therapeutics Market – Opportunity Analysis Index, By Product Type, By Route Of Administration, and Country, 2022-2028
9.5. Europe Multiple Sclerosis Therapeutics Market Dynamics – Trends
10. Asia-Pacific Multiple Sclerosis Therapeutics Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
10.1. Product Type Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.1.1. Immunosuppressants
10.1.2. Immunomodulators
10.2. Route Of Administration Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.2.1. Oral
10.2.2. Injectable
10.2.3. Intravenous
10.3. Country Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
10.3.1. China
10.3.2. India
10.3.3. Japan
10.3.4. ASEAN
10.3.5. Australia & New Zealand
10.3.6. Rest of Asia-Pacific
10.4. Asia-Pacific Multiple Sclerosis Therapeutics Market – Opportunity Analysis Index, By Product Type, By Route Of Administration, and Country, 2022-2028
10.5. Asia-Pacific Multiple Sclerosis Therapeutics Market Dynamics – Trends
11. Latin America Multiple Sclerosis Therapeutics Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
11.1. Product Type Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.1.1. Immunosuppressants
11.1.2. Immunomodulators
11.2. Route Of Administration Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.2.1. Oral
11.2.2. Injectable
11.2.3. Intravenous
11.3. Country Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
11.3.1. Brazil
11.3.2. Mexico
11.3.3. Rest of Latin America
11.4. Latin America Multiple Sclerosis Therapeutics Market – Opportunity Analysis Index, By Product Type, By Route Of Administration, and Country, 2022-2028
11.5. Latin America Multiple Sclerosis Therapeutics Market Dynamics – Trends
12. Middle East and Africa Multiple Sclerosis Therapeutics Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
12.1. Product Type Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.1.1. Immunosuppressants
12.1.2. Immunomodulators
12.2. Route Of Administration Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.2.1. Oral
12.2.2. Injectable
12.2.3. Intravenous
12.3. Country Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
12.3.1. Gulf Cooperation Council (GCC) Countries
12.3.2. South Africa
12.3.3. Rest of MEA
12.4. MEA Multiple Sclerosis Therapeutics Market- Opportunity Analysis Index, By Product Type, By Route Of Administration, and Country, 2022-2028
12.5. MEA Multiple Sclerosis Therapeutics Market Dynamics – Trends
13. Competition Landscape
13.1. Strategic Dashboard of Top Market Players
13.2. Company Profiles (Introduction, Financial Analysis, Key Product Types, Key Developments, Strategies, and SWOT Analysis)
13.2.1. Biogen (U.S.)
13.2.2. Pfizer Inc. (U.S.)
13.2.3. F. Hoffmann-La Roche Ltd. (Switzerland)
13.2.4. Novartis AG (Switzerland)
13.2.5. Merck & Co., Inc. (U.S.)
13.2.6. Sanofi (France)
13.2.7. Teva Pharmaceutical Industries Ltd. (Israel)
13.2.8. Janssen Pharmaceuticals, Inc. (Johnson & Johnson Corporation) (New Jersey)
13.2.9. Bristol-Myers Squibb Company (U.S.)
14. Research Methodology
15. Key Assumptions and Acronyms

Report

Company Profile

  • Biogen (U.S.)
  • Pfizer Inc. (U.S.)
  • Hoffmann-La Roche Ltd. (Switzerland)
  • Novartis AG (Switzerland)
  • Merck & Co., Inc. (U.S.)
  • Sanofi (France)
  • Teva Pharmaceutical Industries Ltd. (Israel)
  • Janssen Pharmaceuticals, Inc. (Johnson & Johnson Corporation) (New Jersey)
  • Bristol-Myers Squibb Company (U.S.)

Description

Multiple Sclerosis Therapeutics Market size is expected to be valued at USD 27,534.2 million in 2022 and is expected to grow at a CAGR of 5.6% in 2022-2028. Multiple sclerosis is a chronic immune-mediated inflammatory disease that disturbs nerve cells in the brain and spinal cord, producing demyelination, neurodegeneration, and axonal transection. muscle relaxants, physical therapy, antidepressants, and injectable, infused, and oral medications are some of the most extensively used therapies. Glatiramer acetate and Interferon-beta are injectable treatments that are provided into the muscle or under the skin, oral medications are teriflunomide, cladribine, and dimethyl fumarate; and intravenous infusion therapies are ocrelizumab, natalizumab, and alemtuzumab. The growing prevalence of multiple sclerosis can lead to the growth of the multiple sclerosis therapeutics markets. Moreover, growing healthcare expenditure which facilitates in refining its infrastructure, and increasing initiatives by private and public organizations to spread awareness are some primary factors that can boost the global multiple sclerosis therapeutics markets. Apart from these, increasing initiatives by private and public organizations to increase awareness, an increase in disposable income, and a surge in the development of advanced interferon, monoclonal antibodies, immunomodulators, and immunosuppressants can also accelerate the market in the future. The growing geriatric population and incessantly changing lifestyles can also drive the global market further. However, some factors such as the high treatment cost of multiple sclerosis and the lack of skilled professionals, and the absence of good healthcare infrastructure in developing nations can restrain the growth of the market. The growing number of research and development events can create an opportunity for the growth of the global multiple sclerosis therapeutics markets.

 

Recent Market Developments:

In march 2021, Janssen Pharmaceutical, Inc. announced the U.S. FDA approval of Ponvory, an oral selective sphingosine-1-phosphate receptor 1 (S1P1) modulator to cure adults with relapsing forms of multiple sclerosis.

In August 2020, Novartis AG announced the U.S. Food and Drug Administration (FDA) approval of Kesimpta (ofatumumab, formerly OMB157) as a subcutaneous injection used for the treatment of relapsing forms of multiple sclerosis

ASIA PACIFIC OFFICE

Precision Business Insights, MIG 366, SAI PLAZA, 1st Floor, KPHB Colony, Hyderabad - 500072

EUROPE OFFICE

Precision Business Insights, Kemp House, 152 – 160 City Road, London EC1V 2NX